Eintrag weiter verarbeiten
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
Gespeichert in:
| Zeitschriftentitel: | Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Cancer Research, 69, 2009, 16, S. 6713-6720 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. |
|---|---|
| author |
Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. |
| spellingShingle |
Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. Cancer Research Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab Cancer Research Oncology |
| author_sort |
faratian, dana |
| spelling |
Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-09-0777 <jats:title>Abstract</jats:title> <jats:p>Resistance to targeted cancer therapies such as trastuzumab is a frequent clinical problem not solely because of insufficient expression of HER2 receptor but also because of the overriding activation states of cell signaling pathways. Systems biology approaches lend themselves to rapid in silico testing of factors, which may confer resistance to targeted therapies. Inthis study, we aimed to develop a new kinetic model that could be interrogated to predict resistance to receptor tyrosine kinase (RTK) inhibitor therapies and directly test predictions in vitro and in clinical samples. The new mathematical model included RTK inhibitor antibody binding, HER2/HER3 dimerization and inhibition, AKT/mitogen-activated protein kinase cross-talk, and the regulatory properties of PTEN. The model was parameterized using quantitative phosphoprotein expression data from cancer cell lines using reverse-phase protein microarrays. Quantitative PTEN protein expression was found to be the key determinant of resistance to anti-HER2 therapy in silico, which was predictive of unseen experiments in vitro using the PTEN inhibitor bp(V). When measured in cancer cell lines, PTEN expression predicts sensitivity to anti-HER2 therapy; furthermore, this quantitative measurement is more predictive of response (relative risk, 3.0; 95% confidence interval, 1.6–5.5; P &lt; 0.0001) than other pathway components taken in isolation and when tested by multivariate analysis in a cohort of 122 breast cancers treated with trastuzumab. For the first time, a systems biology approach has successfully been used to stratify patients for personalized therapy in cancer and is further compelling evidence that PTEN, appropriately measured in the clinical setting, refines clinical decision making in patients treated with anti-HER2 therapies. [Cancer Res 2009;69(16):6713–20]</jats:p> Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab Cancer Research |
| doi_str_mv |
10.1158/0008-5472.can-09-0777 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTA5LTA3Nzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTA5LTA3Nzc |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2009 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2009 |
| issn |
0008-5472 1538-7445 |
| issn_str_mv |
0008-5472 1538-7445 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
faratian2009systemsbiologyrevealsnewstrategiesforpersonalizingcancermedicineandconfirmstheroleofpteninresistancetotrastuzumab |
| publishDateSort |
2009 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Research |
| source_id |
49 |
| title |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_unstemmed |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_full |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_fullStr |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_full_unstemmed |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_short |
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_sort |
systems biology reveals new strategies for personalizing cancer medicine and confirms the role of pten in resistance to trastuzumab |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/0008-5472.can-09-0777 |
| publishDate |
2009 |
| physical |
6713-6720 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Resistance to targeted cancer therapies such as trastuzumab is a frequent clinical problem not solely because of insufficient expression of HER2 receptor but also because of the overriding activation states of cell signaling pathways. Systems biology approaches lend themselves to rapid in silico testing of factors, which may confer resistance to targeted therapies. Inthis study, we aimed to develop a new kinetic model that could be interrogated to predict resistance to receptor tyrosine kinase (RTK) inhibitor therapies and directly test predictions in vitro and in clinical samples. The new mathematical model included RTK inhibitor antibody binding, HER2/HER3 dimerization and inhibition, AKT/mitogen-activated protein kinase cross-talk, and the regulatory properties of PTEN. The model was parameterized using quantitative phosphoprotein expression data from cancer cell lines using reverse-phase protein microarrays. Quantitative PTEN protein expression was found to be the key determinant of resistance to anti-HER2 therapy in silico, which was predictive of unseen experiments in vitro using the PTEN inhibitor bp(V). When measured in cancer cell lines, PTEN expression predicts sensitivity to anti-HER2 therapy; furthermore, this quantitative measurement is more predictive of response (relative risk, 3.0; 95% confidence interval, 1.6–5.5; P &lt; 0.0001) than other pathway components taken in isolation and when tested by multivariate analysis in a cohort of 122 breast cancers treated with trastuzumab. For the first time, a systems biology approach has successfully been used to stratify patients for personalized therapy in cancer and is further compelling evidence that PTEN, appropriately measured in the clinical setting, refines clinical decision making in patients treated with anti-HER2 therapies. [Cancer Res 2009;69(16):6713–20]</jats:p> |
| container_issue |
16 |
| container_start_page |
6713 |
| container_title |
Cancer Research |
| container_volume |
69 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348327595999235 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:09:10.945Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Systems+Biology+Reveals+New+Strategies+for+Personalizing+Cancer+Medicine+and+Confirms+the+Role+of+PTEN+in+Resistance+to+Trastuzumab&rft.date=2009-08-15&genre=article&issn=1538-7445&volume=69&issue=16&spage=6713&epage=6720&pages=6713-6720&jtitle=Cancer+Research&atitle=Systems+Biology+Reveals+New+Strategies+for+Personalizing+Cancer+Medicine+and+Confirms+the+Role+of+PTEN+in+Resistance+to+Trastuzumab&aulast=Harrison&aufirst=David+J.&rft_id=info%3Adoi%2F10.1158%2F0008-5472.can-09-0777&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348327595999235 |
| author | Faratian, Dana, Goltsov, Alexey, Lebedeva, Galina, Sorokin, Anatoly, Moodie, Stuart, Mullen, Peter, Kay, Charlene, Um, In Hwa, Langdon, Simon, Goryanin, Igor, Harrison, David J. |
| author_facet | Faratian, Dana, Goltsov, Alexey, Lebedeva, Galina, Sorokin, Anatoly, Moodie, Stuart, Mullen, Peter, Kay, Charlene, Um, In Hwa, Langdon, Simon, Goryanin, Igor, Harrison, David J., Faratian, Dana, Goltsov, Alexey, Lebedeva, Galina, Sorokin, Anatoly, Moodie, Stuart, Mullen, Peter, Kay, Charlene, Um, In Hwa, Langdon, Simon, Goryanin, Igor, Harrison, David J. |
| author_sort | faratian, dana |
| container_issue | 16 |
| container_start_page | 6713 |
| container_title | Cancer Research |
| container_volume | 69 |
| description | <jats:title>Abstract</jats:title> <jats:p>Resistance to targeted cancer therapies such as trastuzumab is a frequent clinical problem not solely because of insufficient expression of HER2 receptor but also because of the overriding activation states of cell signaling pathways. Systems biology approaches lend themselves to rapid in silico testing of factors, which may confer resistance to targeted therapies. Inthis study, we aimed to develop a new kinetic model that could be interrogated to predict resistance to receptor tyrosine kinase (RTK) inhibitor therapies and directly test predictions in vitro and in clinical samples. The new mathematical model included RTK inhibitor antibody binding, HER2/HER3 dimerization and inhibition, AKT/mitogen-activated protein kinase cross-talk, and the regulatory properties of PTEN. The model was parameterized using quantitative phosphoprotein expression data from cancer cell lines using reverse-phase protein microarrays. Quantitative PTEN protein expression was found to be the key determinant of resistance to anti-HER2 therapy in silico, which was predictive of unseen experiments in vitro using the PTEN inhibitor bp(V). When measured in cancer cell lines, PTEN expression predicts sensitivity to anti-HER2 therapy; furthermore, this quantitative measurement is more predictive of response (relative risk, 3.0; 95% confidence interval, 1.6–5.5; P &lt; 0.0001) than other pathway components taken in isolation and when tested by multivariate analysis in a cohort of 122 breast cancers treated with trastuzumab. For the first time, a systems biology approach has successfully been used to stratify patients for personalized therapy in cancer and is further compelling evidence that PTEN, appropriately measured in the clinical setting, refines clinical decision making in patients treated with anti-HER2 therapies. [Cancer Res 2009;69(16):6713–20]</jats:p> |
| doi_str_mv | 10.1158/0008-5472.can-09-0777 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTA5LTA3Nzc |
| imprint | American Association for Cancer Research (AACR), 2009 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2009 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0008-5472, 1538-7445 |
| issn_str_mv | 0008-5472, 1538-7445 |
| language | English |
| last_indexed | 2024-03-01T18:09:10.945Z |
| match_str | faratian2009systemsbiologyrevealsnewstrategiesforpersonalizingcancermedicineandconfirmstheroleofpteninresistancetotrastuzumab |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 6713-6720 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Research |
| source_id | 49 |
| spelling | Faratian, Dana Goltsov, Alexey Lebedeva, Galina Sorokin, Anatoly Moodie, Stuart Mullen, Peter Kay, Charlene Um, In Hwa Langdon, Simon Goryanin, Igor Harrison, David J. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-09-0777 <jats:title>Abstract</jats:title> <jats:p>Resistance to targeted cancer therapies such as trastuzumab is a frequent clinical problem not solely because of insufficient expression of HER2 receptor but also because of the overriding activation states of cell signaling pathways. Systems biology approaches lend themselves to rapid in silico testing of factors, which may confer resistance to targeted therapies. Inthis study, we aimed to develop a new kinetic model that could be interrogated to predict resistance to receptor tyrosine kinase (RTK) inhibitor therapies and directly test predictions in vitro and in clinical samples. The new mathematical model included RTK inhibitor antibody binding, HER2/HER3 dimerization and inhibition, AKT/mitogen-activated protein kinase cross-talk, and the regulatory properties of PTEN. The model was parameterized using quantitative phosphoprotein expression data from cancer cell lines using reverse-phase protein microarrays. Quantitative PTEN protein expression was found to be the key determinant of resistance to anti-HER2 therapy in silico, which was predictive of unseen experiments in vitro using the PTEN inhibitor bp(V). When measured in cancer cell lines, PTEN expression predicts sensitivity to anti-HER2 therapy; furthermore, this quantitative measurement is more predictive of response (relative risk, 3.0; 95% confidence interval, 1.6–5.5; P &lt; 0.0001) than other pathway components taken in isolation and when tested by multivariate analysis in a cohort of 122 breast cancers treated with trastuzumab. For the first time, a systems biology approach has successfully been used to stratify patients for personalized therapy in cancer and is further compelling evidence that PTEN, appropriately measured in the clinical setting, refines clinical decision making in patients treated with anti-HER2 therapies. [Cancer Res 2009;69(16):6713–20]</jats:p> Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab Cancer Research |
| spellingShingle | Faratian, Dana, Goltsov, Alexey, Lebedeva, Galina, Sorokin, Anatoly, Moodie, Stuart, Mullen, Peter, Kay, Charlene, Um, In Hwa, Langdon, Simon, Goryanin, Igor, Harrison, David J., Cancer Research, Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab, Cancer Research, Oncology |
| title | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_full | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_fullStr | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_full_unstemmed | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_short | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| title_sort | systems biology reveals new strategies for personalizing cancer medicine and confirms the role of pten in resistance to trastuzumab |
| title_unstemmed | Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/0008-5472.can-09-0777 |